{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"31"},{"groupId":"OG007","value":"9"}]}],"title":"Any AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"21"},{"groupId":"OG007","value":"3"}]}],"title":"Any SAE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"32"},{"groupId":"OG007","value":"9"}],"units":"Participants"}],"description":"An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that may require medical or surgical intervention to prevent one of the outcomes mentioned; events of possible study treatment-induced liver injury with hyperbilirubinemia; any new primary cancers; significant cardiac dysfunction; Grade 4 laboratory abnormalities; and drug related hepatobiliary event leading to permanent discontinuation of study treatment. All Treated Population comprised of all participants who received at least one dose of study treatment.","groups":[{"description":"Participants were administered once daily (QD) oral dose of 2 milligrams (mg) GSK525762.","id":"OG000","title":"Part 1: GSK525762 2 mg QD"},{"description":"Participants were administered once daily oral dose of 4 mg GSK525762","id":"OG001","title":"Part 1: GSK525762 4 mg QD"},{"description":"Participants were administered once daily oral dose of 8 mg GSK525762.","id":"OG002","title":"Part 1: GSK525762 8 mg QD"},{"description":"Participants were administered once daily oral dose of 16 mg GSK525762.","id":"OG003","title":"Part 1: GSK525762 16 mg QD"},{"description":"Participants were administered once daily oral dose of 30 mg GSK525762.","id":"OG004","title":"Part 1: GSK525762 30 mg QD"},{"description":"Participants were administered once daily oral dose of 60 mg GSK525762.","id":"OG005","title":"Part 1: GSK525762 60 mg QD"},{"description":"Participants were administered once daily oral dose of 80 mg GSK525762.","id":"OG006","title":"Part 1: GSK525762 80 mg QD"},{"description":"Participants were administered once daily oral dose of 100 mg GSK525762.","id":"OG007","title":"Part 1: GSK525762 100 mg QD"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Treated Population","reportingStatus":"POSTED","timeFrame":"Median of 1.38 months of drug exposure","title":"Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QD","type":"PRIMARY","unitOfMeasure":"Participants"}